The CHEK2-associated breast cancer risk of 20–30% lifetime is not generally high enough to warrant consideration of risk-reducing bilateral mastectomy, but heightened surveillance with additional annual breast MRI is recommended (75). This evidence concerns the gene CHEK2 and breast cancer.